Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2002-10-30
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 620
- Registration Number
- NCT00048230
- Locations
- 🇺🇸
Kaiser Permanente Oncology Clinical Trials, Vallejo, California, United States
🇺🇸Texas Oncology at Medical City Dallas Hospital, Dallas, Texas, United States
🇺🇸Western Pennsylvania Hospital, Dept. of Human Oncology, Pittsburgh, Pennsylvania, United States
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck
- Conditions
- First Posted Date
- 2001-03-01
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00011778
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
- Conditions
- Interventions
- Drug: Myeloma Immunoglobulin Idiotype VaccineDrug: BortezomibDrug: CyclophosphamideBiological: GMCSF (granulocyte macrophage colony stimulating factor)Drug: CyclosporineDrug: Doxorubicin hydrochlorideDrug: EtoposideDrug: Fludarabine phosphateDrug: PrednisoneDrug: Vincristine SulfateDrug: MethotrexateBiological: GCSF (granulocyte colony stimulating factor)
- First Posted Date
- 2000-08-24
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00006184
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.